In This Section

Program

View Abstracts

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress

*Short-talk from Proffered Abstracts

TUESDAY, jANUARY 9

wEDNESDAY, jANUARY 10

Thursday, jANUARY 11

Tuesday, January 9

registration
2:30-7 P.M.

Welcome and Opening Keynote
5:15-6 P.M

  • Welcome from Cochairs
    Susan P. Lees-Miller, University of Calgary, Calgary, Alberta, Canada
    Robert G. Bristow, University of Manchester, Manchester, England
    David K. Cortez, Vanderbilt University School of Medicine, Nashville, Tennessee
  • Introduction of Keynote Speaker
    Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York
  • Single strand DNA GAP accumulation as a functional biomarker for USP1 inhibitor sensitivity
    Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts

Plenary Session 1: Biomarkers for Radiation Sensitivity and DNA Damaging Therapeutics – A Holy Grail?
6-7:30 p.m.

Organized by the AACR Radiation Science and Medicine (RSM) Working Group
Session Chair: Fei-Fei Liu, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

  • Biomarkers for radiation sensitivity and DNA damaging therapeutics 
    Fei-Fei Liu, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  • Molecular and imaging biomarkers of PARP inhibitors for small cell lung cancer
    Benjamin Lok, University of Toronto, Toronto, Ontario, Canada
  • PET imaging predictors of response to chemoradiotherapy in cervical cancer
    Julie K. Schwarz, Washington University School of Medicine St. Louis, Missouri
  • Biomarkers for normal tissue toxicity: DDR genetics and beyond
    Sarah Kerns, Medical College of Wisconsin, Madison, Wisconsin
  • Panel Discussion
    Fei-Fei Liu, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
    Benjamin Lok, University of Toronto, Toronto, Ontario, Canada
    Sarah Kerns, Medical College of Wisconsin, Madison, Wisconsin
    Julie K. Schwarz, Washington University School of Medicine St. Louis, Missouri

pOSTER sESSION a + Opening Reception
7:30-9 P.M.

Wednesday, January 10

Continental Breakfast
7-8 A.M.

Plenary Session 2: Combination Therapy – Radiation DDR Combinations
8-9:45 A.M.

Session Chair: Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York

  • Multifaceted effects of DNA damage response inhibitors on radiation responses of glioblastoma and the normal brain
    Anthony Chalmers, University of Glasgow – Institute of Cancer Sciences, Glasgow, Scotland
  • Targeting the hypoxia-induced DDR to improve radiotherapy response
    Ester M. Hammond, University of Oxford, Gray Institute for Radiation Oncology and Biology, Oxford, England
  • Targeting homologous recombination deficiency (HRD) using optimized ionizing radiation and drug combinations 
    Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, New York
  • DNA damage-induced senescence as a driver of glioblastoma recurrence*
    Sandeep Burma, UT Health Science Center at San Antonio, San Antonio, Texas

Break
9:45-10:15 A.M.

Plenary Session 3: Mutational Spectra
10:15-11:45 A.M.

Session Chair: Marcin Imielinski, NYU Grossman School of Medicine, New York, New York

  • Scars of faulty DNA repair in cancer whole genomes
    Marcin Imielinski, NYU Grossman School of Medicine, New York, New York
  • Molecular archeology of cancer
    Peter Van Loo, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Contributions of TLS and replicative polymerases to UV-induced mutation signatures
    Steven A. Roberts, University of Vermont, Burlington, Vermont

Keynote Lecture II
11:45 a.M. -12:30 p.m.

  • Introduction of Keynote Speaker
    Robert G. Bristow, University of Manchester, Manchester, England
  • Recent advances in mutational signatures of DNA Damage Repair and clinical implications
    Serena Nik-Zainal, University of Cambridge, Cambridge, England

Lunch (On Own)
12:30-2 P.M.

Plenary Session 4: DNA Repair Pathways
2-4 P.M.

Session Chair: Maria Jasin, Memorial Sloan Kettering Cancer Center, New York, New York

  • BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair
    Maria Jasin, Memorial Sloan Kettering Cancer Center, New York, New York
  • Functional screens identify a role for chk1 in early nucleotide excision repair*
    Kent Mouw, Dana-Farber Cancer Institute, Boston, Massachusetts
  • Using systems approaches to interrogate DNA double strand break signaling and repair for optimal tumor cell killing
    Michael B. Yaffe, Koch Institute for Integrative Cancer Research, MIT, Cambridge, Massachusetts
  • DHX9 inhibition as a novel therapeutic for ovarian and breast cancer with loss-of-function mutations in the DNA damage repair genes BRCA1 or BRCA2*
    Jennifer Castro, Accent Therapeutics, Lexington, Massachusetts
  • Replication-coupled and canonical DNA double strand breaks are processed by distinct mechanisms
    Andre Nussenzweig, National Cancer Institute, Bethesda, Maryland

Break
4-4:30 P.M.

PLENARY SESSION 5: Synthetic Lethal Targets
4:30-6:15 P.M.

Session Chair: David K. Cortez, Vanderbilt University Medical Center, Nashville, Tennessee

  • Drugging the DNA damage response (DDR) in the clinic: Going beyond the approved PARP inhibitors
    Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • SMARCAL1 is a selective dependency and a novel synthetic lethal target in ATRX/DAXX mutant ALT+ osteosarcoma and neuroblastoma*
    Lillian M. Guenther, St. Jude Children’s Research Hospital, Memphis, Tennessee
  • GRB2 as a target in the BRCA2-RAD51-MRE11 axis
    John A. Tainer, MD Anderson Cancer Center, Houston, Texas

Spotlight on Proffered Talks (SITA Awardees)
6:15-7:15 p.m.

  • Identification of DNA damage repair genes controlling the immune landscape of breast tumors via spatial functional genomics
    Prerna Suri, Icahn School of Medicine at Mount Sinai, New York, New York
  • Elucidating the effect of PARP inhibitors on MMEJ-mediated DNA repair
    Raquel Ortega, University of Colorado Boulder, Boulder, Colorado
  • The combination of TRIP13 and Aurora kinase A inhibition caused cell cycle specific DNA damage and death in Rb-deficient cancers
    Lacin Yapindi, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Elucidating the mechanistic role of the MRE11-NDRG1 interaction in DNA repair and chemoresistance
    Hanna Doh, Harvard Medical School, Boston, Massachusetts

Poster Session B/Reception
7:15-8:45 P.M.

Thursday, January 11

Continental Breakfast
7-8 A.M.

Plenary Session 6: DNA Damage-Asociated Immune Resposnses
8-9:45 A.M.

Session Chair and Moderator: Robert G. Bristow, University of Manchester, Manchester, England

  • Micronuclei at the nexus of DNA Damage signaling and cytokine production
    Shane Michael Harding, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
  • SMARCAL1 is a dual regulator of innate immunity and PD-L1 expression that promotes tumor immune evasion*
    Giuseppe Leuzzi, Columbia University Irving Medical Center, Columbia, New York
  • A new role of altered R-loop homeostasis in radiation-induced tumor immunogenicity
    Sandra Demaria, Weill Cornell Medicine, New York, New York
  • Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and type-1 interferon expression in cells treated with ATR kinase inhibitors
    Christopher J. Bakkenist, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
  • Panelists:
    Shane Michael Harding, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
    Sandra Demaria, Weill Cornell Medicine, New York, New York
    Christopher J. Bakkenist, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Break
9:45 -10 A.M.

Plenary Session 7: Replication Stress
10-11:45 a.m.

Session Chair: Agata Smogorzewska, The Rockefeller University, New York, New York

  • The role of RTF2 in replication and replication stress response
    Agata Smogorzewska, The Rockefeller University, New York, New York
  • Mechanistic insights into how RADX regulates RAD51 nucleoprotein filaments to maintain genome stability and control replication stress responses
    David K. Cortez, Vanderbilt University Medical Center, Nashville, Tennessee
  • Understanding extrachromosomal telomere generation in ALT cancers*
    Jaewon Min, Columbia University Irving Medical Center, Columbia, New York
  • DNAJC9-a novel regulator of the MCM complex
    Dipanjan Chowdhury, Dana-Farber Cancer Institute, Boston, Massachusetts

Lunch (Provided)
11:45 a.m.-12:15 p.m.

Plenary Session 8: Acquired resistance to DDR inhibitors
12:15-2:00 p.m.

Session Chair: Susan P. Lees-Miller, University of Calgary, Alberta, Canada

  • Understanding and overcoming resistance to PARP inhibitors in cancer therapy
    Jos M. M. Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Novel role of glycogen synthase kinase-3β in determining cancer cell response to PARPi through regulation of 53BP1 function*
    Fen Xia, University of Arkansas for Medical Sciences, Little Rock, Arkansas
  • DNA repair inhibitor and immunologic strategies for reversal of PARP inhibitor resistance
    Geoffrey I. Shapiro, Harvard Medical School, Boston, Massachusetts
  • Role of BRCA2 in determining aggression in localised prostrate cancer
    Robert G. Bristow, University of Manchester, Manchester, England
  • Enhancing radiation-induced anti-tumoral immune responses with PARP inhibitors in pancreatic cancer from laboratory studies to clinical trials
    Meredith A. Morgan, University of Michigan, Ann Arbor, Michigan

Closing Remarks
2:00 p.m

Robert G. Bristow, University of Manchester, Manchester, England